News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
718,895 Results
Type
Article (41402)
Company Profile (271)
Press Release (677216)
Multimedia
Podcasts (98)
Webinars (17)
Section
Business (204915)
Career Advice (2041)
Deals (35604)
Drug Delivery (108)
Drug Development (81609)
Employer Resources (174)
FDA (16436)
Job Trends (14989)
News (346918)
Policy (32873)
Tag
Academia (2568)
Accelerated approval (24)
Adcomms (26)
Allergies (122)
Alliances (49659)
ALS (157)
Alzheimer's disease (1624)
Antibody-drug conjugate (ADC) (269)
Approvals (16606)
Artificial intelligence (455)
Autoimmune disease (116)
Automation (33)
Bankruptcy (362)
Best Places to Work (11661)
BIOSECURE Act (21)
Biosimilars (173)
Biotechnology (177)
Bladder cancer (145)
Brain cancer (52)
Breast cancer (589)
Cancer (4390)
Cardiovascular disease (364)
Career advice (1717)
Career pathing (34)
CAR-T (261)
CDC (48)
Celiac Disease (1)
Cell therapy (683)
Cervical cancer (34)
Clinical research (69118)
Collaboration (1464)
Company closure (4)
Compensation (1032)
Complete response letters (47)
COVID-19 (2808)
CRISPR (82)
C-suite (684)
Cystic fibrosis (135)
Data (5659)
Decentralized trials (2)
Denatured (25)
Depression (112)
Diabetes (456)
Diagnostics (6604)
Digital health (38)
Diversity (11)
Diversity, equity & inclusion (45)
Drug discovery (212)
Drug pricing (174)
Drug shortages (28)
Duchenne muscular dystrophy (212)
Earnings (89754)
Editorial (52)
Employer branding (22)
Employer resources (152)
Events (116603)
Executive appointments (940)
FDA (19166)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (7)
Frontotemporal dementia (20)
Funding (1317)
Gene editing (181)
Generative AI (38)
Gene therapy (546)
GLP-1 (929)
Government (4698)
Grass and pollen (6)
Guidances (375)
Healthcare (18889)
HIV (48)
Huntington's disease (39)
IgA nephropathy (75)
Immunology and inflammation (230)
Immuno-oncology (36)
Indications (75)
Infectious disease (3055)
Inflammatory bowel disease (181)
Inflation Reduction Act (13)
Influenza (102)
Intellectual property (209)
Interviews (318)
IPO (16628)
IRA (51)
Job creations (3679)
Job search strategy (1444)
Kidney cancer (15)
Labor market (79)
Layoffs (548)
Leadership (28)
Legal (7999)
Liver cancer (88)
Longevity (12)
Lung cancer (606)
Lymphoma (347)
Machine learning (37)
Management (59)
Manufacturing (671)
MASH (153)
Medical device (13684)
Medtech (13720)
Mergers & acquisitions (19940)
Metabolic disorders (1159)
Multiple sclerosis (143)
NASH (16)
Neurodegenerative disease (278)
Neuropsychiatric disorders (69)
Neuroscience (2705)
NextGen: Class of 2025 (6533)
Non-profit (4506)
Now hiring (60)
Obesity (543)
Opinion (255)
Ovarian cancer (150)
Pain (172)
Pancreatic cancer (189)
Parkinson's disease (251)
Partnered (31)
Patents (450)
Patient recruitment (388)
Peanut (53)
People (58668)
Pharmaceutical (63)
Pharmacy benefit managers (28)
Phase I (21528)
Phase II (30419)
Phase III (22717)
Pipeline (3762)
Policy (273)
Postmarket research (2570)
Preclinical (9171)
Press Release (64)
Prostate cancer (216)
Psychedelics (45)
Radiopharmaceuticals (261)
Rare diseases (711)
Real estate (5963)
Recruiting (70)
Regulatory (23999)
Reports (51)
Research institute (2378)
Resumes & cover letters (355)
Rett syndrome (23)
RNA editing (12)
RSV (79)
Schizophrenia (135)
Series A (214)
Series B (165)
Service/supplier (11)
Sickle cell disease (92)
Special edition (22)
Spinal muscular atrophy (153)
Sponsored (40)
Startups (3628)
State (2)
Stomach cancer (16)
Supply chain (99)
Tariffs (87)
The Weekly (71)
Vaccines (1007)
Venture capital (73)
Weight loss (357)
Women's health (74)
Worklife (17)
Date
Today (117)
Last 7 days (580)
Last 30 days (2395)
Last 365 days (30333)
2025 (29617)
2024 (35298)
2023 (40146)
2022 (51240)
2021 (55816)
2020 (54167)
2019 (46585)
2018 (35076)
2017 (32216)
2016 (31595)
2015 (37612)
2014 (31378)
2013 (26373)
2012 (28610)
2011 (29299)
2010 (27357)
Location
Africa (742)
Alabama (77)
Alaska (7)
Arizona (288)
Arkansas (13)
Asia (39048)
Australia (6371)
California (10363)
Canada (3083)
China (972)
Colorado (433)
Connecticut (447)
Delaware (308)
Europe (84187)
Florida (1535)
Georgia (330)
Hawaii (2)
Idaho (61)
Illinois (778)
India (54)
Indiana (488)
Iowa (20)
Japan (360)
Kansas (122)
Kentucky (36)
Louisiana (24)
Maine (70)
Maryland (1305)
Massachusetts (7479)
Michigan (300)
Minnesota (583)
Mississippi (5)
Missouri (119)
Montana (30)
Nebraska (26)
Nevada (111)
New Hampshire (73)
New Jersey (2796)
New Mexico (28)
New York (2764)
North Carolina (1352)
North Dakota (8)
Northern California (4971)
Ohio (305)
Oklahoma (20)
Oregon (38)
Pennsylvania (2122)
Puerto Rico (19)
Rhode Island (45)
South America (1106)
South Carolina (58)
South Dakota (1)
Southern California (4010)
Tennessee (162)
Texas (1594)
United States (37034)
Utah (306)
Vermont (1)
Virginia (237)
Washington D.C. (78)
Washington State (849)
West Virginia (4)
Wisconsin (89)
Wyoming (2)
718,895 Results for "pfizer inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Pfizer’s Cost Cuts Claim 200+ Jobs in Switzerland: Report
Pfizer is in the midst of an aggressive, multi-year cost-cutting effort, which so far has left nearly 2,000 people jobless.
December 11, 2025
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
Pfizer’s Winning Bid for Metsera Concludes ‘Real Housewives of Biopharma’
The deal is done. What happens next for Pfizer and Metsera—and Novo?
November 10, 2025
·
3 min read
·
Annalee Armstrong
Legal
Delaware Court Denies Pfizer’s Bid To Block Novo-Metsera Deal
The court’s decision allows Metsera to walk away from its previous acquisition agreement with Pfizer in favor of Novo Nordisk’s higher bid.
November 6, 2025
·
2 min read
·
Tristan Manalac
Vaccines
Pfizer CEO Blasts HHS’ Anti-Vaccine Policies as Revenue Outlook Dims
Pfizer CEO Albert Bourla defended his company’s vaccine business as rhetoric from HHS Secretary Robert F. Kennedy Jr. drives a notable drop in COVID-19 sales.
December 16, 2025
·
3 min read
·
Annalee Armstrong
Mergers & acquisitions
Pfizer Is Not a Done Dealmaker After Metsera Buy, With $6B More To Spend
With $6 billion left in firepower, Pfizer is planning transactions in the hundreds of millions to the low-billions range, particularly in internal medicine and immunology and inflammation, Guggenheim reported.
December 10, 2025
·
1 min read
·
Annalee Armstrong
Mergers & acquisitions
Novo Ups Ante In Metsera Buyout Drama With $10B Offer, Beating Pfizer’s New Bid
Both companies have submitted revised bids, with Novo’s coming in $1.9 billion higher than Pfizer’s.
November 4, 2025
·
1 min read
·
Annalee Armstrong
Drug pricing
Pfizer’s Drug Pricing Deal With Trump Raises Questions About Access
At the heart of the agreement is Pfizer’s $70 billion commitment to U.S.-based manufacturing and an exemption from tariffs for three years. While the reaction was mostly positive from Wall Street, other observers noted that the benefits for patients are unclear at best.
October 1, 2025
·
2 min read
·
Dan Samorodnitsky
Mergers & acquisitions
Pfizer Closes Metsera Deal, Officially Ending Bidding War Drama
Speaking at a conference this morning, Pfizer CEO Albert Bourla suggested that Metsera’s therapies could begin hitting the market in 2028.
November 13, 2025
·
1 min read
·
Annalee Armstrong
Earnings
Pfizer Fields Novo’s $10B Curveball, With Bourla Promising To Fight for Metsera
Due to the litigation Pfizer filed Friday and Monday against Metsera, Novo Nordisk and the biotech’s lead shareholder, CEO Albert Bourla was limited in what he could say. But he said Pfizer was the best fit for Metsera.
November 4, 2025
·
5 min read
·
Annalee Armstrong
Obesity
After Metsera Battle, Pfizer Heads to China for Another Obesity Deal Worth up to $1.9B
Pfizer apparently had more in the tank after the high-profile battle to acquire Metsera earlier this fall. The company has licensed a new GLP-1 from YaoPharma.
December 9, 2025
·
2 min read
·
Dan Samorodnitsky
1 of 71,890
Next
